Back to Newsroom

Advanced Cell Technology Announces Final Patient Treated in Stargardt’s Macular Degeneration Phase 1 Trial in the United Kingdom

MARLBOROUGH, Mass.– Advanced Cell Technology, Inc. (“ACT”; OTCBB:ACTCD), a leader in the field of regenerative ophthalmology, announced today that it has completed treatment of the final patient in its U.K. based Phase 1 clinical trial for Stargardt’s macular degeneration (SMD). The successful transplantation of the Company’s proprietary RPE cells in the last patient of twelve represents the completion of the enrollment stage of this trial. The trial is a prospective, open-label study designed to determine the safety and tolerability of the Company’s RPE cell therapy following sub-retinal transplantation into patients.

Click here to read more